Background: It is critical to manage acute postoperative pain for patient satisfaction and better outcome. Erector spinae plane block (ESPB) can produce sensory blocking on both visceral and somatic levels. This study aimed to evaluate the ESPB efficacy in controlling acute postoperative pain in open nephrectomy for renal malignancies.
Methods: This prospective randomized, controlled, open-label trial included 60 cases scheduled for open nephrectomy for renal malignancy under general anesthesia. Cases were assigned randomly into two equal groups. Group E administered continuous preoperative unilateral ESPB (20mL bupivacaine 0.25% bolus then 6 mL/h 0.1% for 48 hours). Group C administered intravenous (IV) patient-controlled analgesia (PCA) morphine (0.01 mg/kg/h). Postoperative analgesia was managed by morphine (3 mg IV in group E or 0.01 mg/kg bolus with a 15-min lockout in group C) to keep the visual analog scale (VAS) scores <4.
Results: Intraoperative fentanyl consumption and total morphine consumption in 1st 48 hours postoperatively were significantly lower in group E than group C (P= 0.001 and <0.001, respectively). The time to first analgesic request was significantly longer in group E than group C (P <0.001). VAS scores at movement and rest were significantly lower in group E than group C (P <0.001).
Conclusion: In renal malignancies, ESPB provided better analgesia with prolonged time and lower pain scores at both rest and movement compared to IV PCA following open nephrectomy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531616 | PMC |
http://dx.doi.org/10.2147/JPR.S379721 | DOI Listing |
Sci Rep
January 2025
Department of Urology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda, Shinagawa-ku, Tokyo, 141-8625, Japan.
Partial nephrectomy has become the gold standard treatment for small renal masses. This study aimed to assess the impact of soft coagulation hemostasis on parenchymal volume reduction of the operated kidney after an open partial nephrectomy. We retrospectively reviewed 94 patients with small renal tumors who underwent open partial nephrectomy with soft-coagulation hemostasis at our institution.
View Article and Find Full Text PDFJ Nephrol
January 2025
Townsville Hospital and Health Service, Douglas, QLD, 4814, Australia.
Background: Renal cell carcinoma (RCC) is a common malignancy, and nephrectomy is the mainstay of treatment for non-metastatic disease. The choice of surgery depends on the risks of oncologic recurrence, kidney function decline, and perioperative complications. This study aimed to identify factors associated with adverse post-operative outcomes in RCC patients undergoing nephrectomy at Townsville University Hospital (TUH).
View Article and Find Full Text PDFCureus
December 2024
Department of Urology, Mamata Academy of Medical Sciences, Bachupally, IND.
This case series elucidates renal cell carcinoma characterized by three distinct presentations, necessitating individualized treatment strategies tailored to each specific circumstance. The three cases presented pertain to clear cell renal cell carcinoma. The first case involves a 44-year-old male patient with renal cell carcinoma in an ectopic kidney, an exceedingly rare occurrence with limited literature.
View Article and Find Full Text PDFEur Urol Open Sci
January 2025
Department of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Background And Objective: Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study.
Methods: Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC.
SAGE Open Med Case Rep
January 2025
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Clear cell renal cell carcinoma is the predominant subtype of kidney cancer. With distant metastasis, the overall survival rate for patients with renal cell carcinoma decreases significantly compared to localized disease. However, pembrolizumab plus axitinib combination is safe and improves long-term survival.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!